Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 2Lutetium-177 2Liquid Biopsy 2Endoscopic Mucosal Resection 2Data Collection 2pentetreotide 1fluorodopa F 18 1copper dotatate CU-64 1Yttrium-90 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Single Photon Emission Computed Tomography Computed Tomography 1Serum Albumin 1Robotic Surgical Procedures 1Resveratrol 1Respiratory Therapy 1Referral and Consultation 1Radiofrequency Ablation 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Palliative Care 1Octreotide 1Nutrition Assessment 1Needles 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Drug Therapy 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × copper dotatate CU-64 × NET × Clear all
NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed
39 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡